Status:
COMPLETED
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead Sponsor:
St. Jude Children's Research Hospital
Conditions:
Acute Lymphoblastic Leukemia
Lymphoma, Lymphoblastic
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what...
Detailed Description
In this study, subjects will be divided into high-risk and standard-risk subgroups according to the length of their first remission, the type of early cancer cell (T or B-cell) and the site or sites o...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Childhood ALL in first relapse OR in first hematological relapse after an extramedullary relapse, OR not attaining a complete remission with frontline therapies, OR lymphoblastic leukemia in first relapse.
- Patients must be 21 years of age or younger
- Informed consent explained to and signed by parent/legal guardian.
- Exclusion Criteria
- Life expectancy less than 8 weeks
- Patients with mature B cell ALL
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00186875
Start Date
November 1 2003
End Date
August 1 2016
Last Update
July 28 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rady Children's Hospital and Health Center
San Diego, California, United States, 92123
2
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105